_edited.jpg

UNADDRESSED MARKET

With no FDA on-label treatment for PCV available, SalutarisMD is the first company to seek FDA market approval to treat PCV.

CURRENT MARKET

20+ MILLION PEOPLE SUFFER FROM WET-AMD 

+

15+ BILLION IN ANTI-VEGF SALES

+

UP TO 60% EXPERIENCE INADEQUATE RESULTS

 

=

MASSIVE OPPORTUNITY

WET AGE-RELATED MACULAR DEGENERATION

THE ESTIMATED NUMBER OF INDIVIDUALS WITH AMD FOR 2020 IS 196+ MILLION

20+M

20+ MILLION SUFFER FROM THE ADVANCED FORM OF AMD

8+M

WE ESTIMATE THAT UP TO 8+ MILLION ARE RESISTANT TO ANTI-VEGF THERAPY

$15+B

THE INJECTION INDUSTRY FOR

ANTI-VEGF IS A $15+ BILLION INDUSTRY

AND GROWING

Phoropter

THE MARKET LANDSCAPE

  • Currently, we estimate the majority of afflicted seniors go untreated or under treated.

 

  • Of those treated, up to 60% suffer inadequate results due to their subtype, which is often PCV.

  • SMD plans to address this treatment failure with BetaCurve.

  • Our upcoming pivotal study will establish efficacy for PCV.

  • In addition, BetaCurve's one-time, 10-minute procedure may prove to be the only alternative for those who can't afford or access frequent and ongoing injections.

GROWING AWARENESS

Historically, PCV has gone undetected in the U.S.
 
Recent advances in imaging technology are driving a new awareness.

PCV is now part of the ophthalmology curriculum at top universities.

Untitled design (56).png

NEXT STEP

A different approach that changes the outlook

In early 2022, SalutarisMD will commence a pivotal study to receive FDA on-label approval for the indication of PCV, the first of several indications that can be treated with our device.

SUMMARY

WET-AMD CAUSE

Untitled design (66).png

Disease activity is charaterized by abnormal fluid and blood leakage at the back of the eye from undesirable capillary growth. 

CURRENT TREATMENT 

The first year requirement is 8-12 anti-VEGF injections and continues indefinitely. Up to 60% suffer inadequate results after the first year and will stop treatment altogether.

Untitled design (68).png

ANTI-VEGF LIMITATIONS

Untitled design (69).png

The arteriolized vessels are largely unaffected by anti-VEGF. Repeated injections never fully eliminate the root cause.

ANTI-VEGF PATIENTS

Untitled design (71).png

White people typically suffer from classic wet-AMD that can be treated effectively with ongoing anti-VEGF monotherapy.

HIGH RISK EYES

Untitled design (71).png

Asian and Black people are more likely to suffer from the PCV sub-type of wet-AMD that does not respond well to anti-VEGF monotherapy.

BETACURVE GIVES HOPE

side-angle-2.png

The BetaCurve™ is designed to treat all types of patients. The mechanism of action of beta radiation on neovascularization has been studied for over 50-years.

SalutarisMD's vision for the future:
convenient, accessible, affordable treatment for all.